Icosavax (NASDAQ:ICVX – Get a rating) is one of 259 publicly traded companies in the Biologics, Except Diagnostics sector, but how does it stand out from its peers? We will compare Icosavax to similar companies based on the strength of its profitability, analyst recommendations, valuation, institutional ownership, earnings, risk and dividends.
This is a breakdown of recent ratings from Icosavax and its peers, provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
Icosavax currently has a consensus price target of $48.57, suggesting a potential upside of 683.33%. As a group, the “Biologicals, excluding diagnostics” companies have an upside potential of 112.02%. Given Icosavax’s stronger consensus rating and higher likely upside, equity research analysts clearly believe Icosavax is more favorable than its peers.
Institutional and Insider Ownership
79.4% of Icosavax shares are held by institutional investors. In comparison, 53.0% of the shares of all “Biologicals, except diagnostics” companies are held by institutional investors. 16.7% of the shares of all Biologics excluding Diagnostics companies are held by insiders. Strong institutional ownership indicates that hedge funds, large money managers, and endowments believe a company is poised for long-term growth.
This table compares the net margins, return on equity and return on assets of Icosavax and its peers.
|Net margins||Return on equity||return on assets|
Valuation and benefits
This chart compares the revenue, earnings per share (EPS), and valuation of Icosavax and its peers.
|Gross revenue||Net revenue||Price/earnings ratio|
|icosavax||$7.80 million||-$66.97 million||-1.19|
|Icosavax competitors||$773.46 million||$147.16 million||0.23|
Icosavax peers have higher revenue and profit than Icosavax. Icosavax trades at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Icosavax beats its peers on 6 of the 11 factors compared.
About Icosavax (Get a rating)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in development include IVX-121, a vaccine candidate targeting RSV and is in Phase 1/1b clinical trials; IVX-A12, a candidate monovalent respiratory syncytial virus (RSV) antigen with bivalent RSV/human metapneumovirus (hMPV) target indication; IVX-241, a vaccine candidate with an hMPV target; and IVX-411, a novel receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is in Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Get news and reviews for Icosavax Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Icosavax and related companies with MarketBeat.com’s FREE daily newsletter.